Revolution Medicines Inc
| Fiscal year | Operating cash flow | Stock comp | Capex | Free cash flow | Net borrowing | FCFE | Shares (B) | FCF per share | Year-end price | FCF yield |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.1 | 0.0 | 0.0 | -0.2 | 0.0 | -0.2 | 0.07 | $-2.40 | $25.17 | -9.5% |
| 2022 | -0.2 | 0.0 | 0.0 | -0.3 | 0.0 | -0.3 | 0.08 | $-3.30 | $23.82 | -13.9% |
| 2023 | -0.4 | 0.1 | 0.0 | -0.4 | 0.0 | -0.4 | 0.11 | $-3.71 | $28.68 | -12.9% |
| 2024 | -0.6 | 0.1 | 0.0 | -0.6 | 0.0 | -0.6 | 0.17 | $-3.86 | $43.74 | -8.8% |
| 2025 | -0.9 | 0.1 | 0.0 | -1.0 | 0.0 | -1.0 | 0.19 | $-5.43 | $79.65 | -6.8% |
| 4-yr CAGR | n/m | 54.6% | 25.1% | n/m | n/a | n/m | 27.1% | n/m | 33.4% | avg -10.4% |
| Fiscal year | Revenue | EBITDA | EBITDA margin | Debt incl. leases | Cash & securities | Market cap | Enterprise value | EV / EBITDA | Net debt / EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| 2021 | 0.0 | -0.2 | -614.8% | 0.1 | 0.6 | 2 | 1 | n/m | n/m |
| 2022 | 0.0 | -0.2 | -702.7% | 0.1 | 0.6 | 2 | 1 | n/m | n/m |
| 2023 | 0.0 | -0.5 | -4,126.7% | 0.1 | 1.9 | 3 | 1 | n/m | n/m |
| 2024 | 0.0 | -0.7 | n/m | 0.1 | 2.3 | 7 | 5 | n/m | n/m |
| 2025 | 0.0 | -1.2 | n/m | 0.2 | 2.0 | 15 | 13 | n/m | n/m |
| 4-yr CAGR | n/m | n/m | avg -1,814.7% | 24.2% | 36.9% | 69.5% | 78.0% | median n/m | avg n/m |
Revenue grew n/m a year and EBITDA n/m a year from FY2021 to FY2025, and free cash flow after stock compensation did not grow from a positive base. The share count rose 27.1% a year, so per-share figures grew more slowly than the totals. The balance sheet carried more cash than debt in every one of those years. Capital spending rose from 22% of revenue to ∞%, which is why free cash flow lagged operating cash flow in the latest year.
From the data: EBITDA was not positive in enough years to set a growth rate and an exit multiple, so there is no hurdle price. The share count moved 40% in FY2023 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis. The share count moved 48% in FY2024 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis.
- Free cash flow is operating cash flow less stock-based compensation less capital spending. Stock comp is treated as a real cost.
- Net borrowing is the year's change in long-term debt. FCFE adds it back to free cash flow, the classic one-page definition.
- EBITDA is operating income plus depreciation and amortization. Debt includes lease obligations; cash includes short-term investments.
- Market cap uses the fiscal year-end price as traded, restated for later splits but not for dividends; enterprise value adds debt and subtracts cash.
- Share count is the yearly change in shares outstanding over the period; flat or falling clears. Cash margin is the latest free cash flow margin against its three-year average; within two points clears.
- Hurdle price is the present value, at the hurdle rate, of ten years of modeled free cash flow per share plus a year-10 sale at the exit multiple. It is shown as an exhibit: the 2011 to 2021 back-test found that buying below it did not sort winners from losers, so it is not scored.
- Cleared on a check means the number clears the stated rule; Not cleared means it does not. Durable, Holding and First year say how many fiscal years running the company has cleared all four staying-power checks (four or more, two or three, one); Partial and Not cleared count the checks it clears today. All of it is fact about the filings, not a rating of the stock.